Helixgate

Helixgate

Uncategorized

New Human-Computer Interaction Software Designed to Support Diverse Online Teamwork Styles

Published

on

Remote collaboration software tools, such as Zoom or Google Docs, have become essential for teamwork. But they often overlook the fact that people do not all approach collaboration in the same way, according to researchers at North Carolina State University (NCSU).

Scientists report that they have now developed a new human-computer interaction (HCI) method called RemoteCollabEval (RCE) to identify barriers to collaboration and inclusivity, allowing designers and developers to build software features that better support diverse teamwork styles.

The work is part of the broader HCI field, which examines how people use digital systems and how interfaces can be optimized for clarity and ease of use.

“At present, most remote collaboration platforms are evaluated by designers and developers using established HCI inspection methods,” says Sandeep Kuttal, PhD, the principal investigator behind the work and an associate professor of computer science at NCSU. “One of the most widely used inspection methods is a ‘groupware walkthrough,’ where designers essentially play out how a collaborative effort might unfold between two or three hypothetical users. However, these methods typically assume all users behave in similar ways.”

As senior author of a paper, “Equity by Design: A New HCI Method for Surfacing Inclusivity Issues in Remote Collaboration Software,” that will be presented at the ACM Designing Interactive Systems Conference (DIS 2026) in Singapore, from June 13-17, Kuttal notes that “It’s well-established that people from various backgrounds often have different collaboration and communication styles. “Existing HCI inspection methods don’t account for these differences, which limits how inclusive and effective these tools can be. That’s what we set out to address.”

Six key personality facets

As a first step, the researchers drew on established social science and software engineering research to identify six key personality facets that influence collaborative behavior:

  • Leadership style: Does the individual take a democratic or authoritative approach?
  • Interruption style: Does the individual interrupt others or wait for cues?
  • Non-verbal cues: Is the individual expressive or reserved in digital spaces?
  • Relationship-seeking: Does the individual focus on building rapport or primarily on achieving goals?
  • Social awareness: Is the individual attentive to or unaware of what their teammates are doing?
  • Collaborative self-efficacy: How confident is the individual in the group’s ability to perform?

The researchers then created hypothetical users called “personas,” which are detailed representations of different types of users that incorporate descriptions of each of the six facets. These personas allow designers to simulate interpersonal friction and uncover “inclusivity bugs” that might otherwise go unnoticed during standard testing.

“Because we have descriptions of all six facets for each persona, we can incorporate those key characteristics into our assessment of how well a given platform allows for effective collaboration between people of different backgrounds,” explains Kuttal.

The team then modified existing groupware walkthrough methods, requiring designers and developers to explicitly consider these six facets as part of the process and created a specialized walkthrough. This combination of personas that account for personality facets and the specialized walkthrough forms the RCE method.

As a proof-of-concept study, the scientists recruited 29 undergraduate and graduate students and split them into 10 teams. Five teams inspected an existing remote collaboration platform using the conventional Groupware Walkthrough method; the other five teams inspected the same platform using RCE.

“The teams who used the RCE method identified six times more inclusivity issues than the conventional method,” continues Kuttal. “Essentially, RCE did a better job of identifying when conflicting styles would make collaboration between personas difficult. This is important, because identifying these challenges gives designers and developers an opportunity to modify features and user interfaces to improve these remote collaborative platforms. And, ultimately, to improve collaboration itself.

“Because RCE is a standardized, systematic method, it can be used by designers and developers anywhere. It doesn’t require a huge budget, or an expensive research effort. It’s a method that can easily be used to make these platforms better.”

The post New Human-Computer Interaction Software Designed to Support Diverse Online Teamwork Styles appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

QurAlis’ Phase 2 data bolster case for genetic approach to sporadic ALS

Published

on

Biogen’s Qalsody won FDA approval in 2023 to treat a rare, genetic form of amyotrophic lateral sclerosis. On Tuesday, QurAlis presented interim Phase 2 data showing the potential of a similar drug to more broadly treat the neurodegenerative disease.

Continue Reading

Uncategorized

Madrigal extends MASH deal streak with Arrowhead drug that J&J didn’t want

Published

on

Madrigal Pharmaceuticals has made its fourth MASH deal in 10 months, further signaling its ambitions to be not just the first drugmaker for the fatty liver disease, but also the owner of the field’s broadest …

Continue Reading

Uncategorized

STAT+: Pharmalittle: We’re reading about RFK Jr. targeting antidepressants, J&J pushing an IBD drug, and more

Rise and shine, another busy day is on the way. However, this is also shaping up as a beautiful day as well, given the clear and sunny skies — and delicious breezes — enveloping the Pharmalot campus this morning. This calls for celebration with a cup of stimulation, and we are opening a new package of cinnamon buns for the occasion. Spring has sprung, after all. What is upon us right now, however, is our ever-growing to-do list. Sound familiar? So here are some items of interest. Have a great day, everyone. …

U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced several initiatives intended to rein in the prescription of selective serotonin reuptake inhibitors, the most widely prescribed class of antidepressants, which he has described as exceptionally difficult to quit, The New York Times writes. The initiative focuses on the most widely prescribed class of psychiatric medications, first-line treatments for depression and anxiety that include Zoloft, Lexapro, Paxil, and Prozac. In 2026. 16.7% of U.S. adults, or roughly one in six, reported currently taking one of these pills. The changes — new trainings, reimbursement mechanisms, and clinical guidelines — nudge clinicians to help patients get off medications, and to consider non-pharmaceutical interventions, like therapy, nutrition, and exercise.

A closely watched therapy developed by Johnson & Johnson failed to show a statistically meaningful improvement for patients with inflammatory bowel disease. But the company plans to advance the drug into late-stage testing, focusing on a growing subgroup of patients, STAT tells us. On Tuesday, trial investigators presented the results of a study that tested how well combining the drugs Tremfya and Simponi would stop the immune system from mistakenly attacking healthy tissues in the digestive tract. J&J tested the combined therapy in two Phase 2b clinical trials hitting both major forms of inflammatory bowel disease — ulcerative colitis and Crohn’s disease. In each trial, the combination performed better than the individual drugs, but did not meet the primary endpoint of clinical remission. 

Continue to STAT+ to read the full story…

Read More

Published

on

Rise and shine, another busy day is on the way. However, this is also shaping up as a beautiful day as well, given the clear and sunny skies — and delicious breezes — enveloping the Pharmalot campus this morning. This calls for celebration with a cup of stimulation, and we are opening a new package of cinnamon buns for the occasion. Spring has sprung, after all. What is upon us right now, however, is our ever-growing to-do list. Sound familiar? So here are some items of interest. Have a great day, everyone. …

U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced several initiatives intended to rein in the prescription of selective serotonin reuptake inhibitors, the most widely prescribed class of antidepressants, which he has described as exceptionally difficult to quit, The New York Times writes. The initiative focuses on the most widely prescribed class of psychiatric medications, first-line treatments for depression and anxiety that include Zoloft, Lexapro, Paxil, and Prozac. In 2026. 16.7% of U.S. adults, or roughly one in six, reported currently taking one of these pills. The changes — new trainings, reimbursement mechanisms, and clinical guidelines — nudge clinicians to help patients get off medications, and to consider non-pharmaceutical interventions, like therapy, nutrition, and exercise.

A closely watched therapy developed by Johnson & Johnson failed to show a statistically meaningful improvement for patients with inflammatory bowel disease. But the company plans to advance the drug into late-stage testing, focusing on a growing subgroup of patients, STAT tells us. On Tuesday, trial investigators presented the results of a study that tested how well combining the drugs Tremfya and Simponi would stop the immune system from mistakenly attacking healthy tissues in the digestive tract. J&J tested the combined therapy in two Phase 2b clinical trials hitting both major forms of inflammatory bowel disease — ulcerative colitis and Crohn’s disease. In each trial, the combination performed better than the individual drugs, but did not meet the primary endpoint of clinical remission. 

Continue to STAT+ to read the full story…

Read More

Continue Reading
Advertisement

Trending